+ New Watchlist

Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

PsyBio Therapeutics

PSYBFOTCEM

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.000001

At close: Aug 25, 4:00 PM EDT

$0.1150

0.1111499900.00%

After Hours: Aug 25, 4:00 PM EDT

PsyBio Therapeutics (PSYBF) Forecast

News

Earnings PsyBio Therapeutics (PSYBF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for PsyBio Therapeutics (OTC:PSYBF) Stock

PsyBio Therapeutics Stock (OTC: PSYBF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, June 08, 2023

MA, FL And OH Psychedelics Scientists And Educators' Latest Research And Views
Lara Goldstein

Friday, April 14, 2023

EXCLUSIVE: In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
Joana Scopel

Tuesday, December 13, 2022

Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More
Lara Goldstein

Monday, December 12, 2022

Psychedelics & Environmental Protection: Company Seeks Patents To Synthetically Produce Toad Venom
Lara Goldstein

Wednesday, December 07, 2022

Psychedelics Production Methods Expect Further IP Protection With 4 New Patents
Lara Goldstein

Tuesday, December 06, 2022

Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Lara Goldstein

Friday, December 02, 2022

PsyBio Therapeutics Reports Interim Third Quarter 2022 Financial Results
Joana Scopel

Tuesday, October 11, 2022

Yeast Produces Bread And Psilocybin, This Company Is Moving Into Clinical Trial Phase
Lara Goldstein

Tuesday, September 06, 2022

Most, But Not All, Psychedelics Companies Have Sufficient Liquidity
Viridian Capital Advisors

Monday, August 29, 2022

DMT Producer PsyBio And Shrooms Grower Red Light Holland Share Their Most Recent Financial Results
Lara Goldstein

Friday, April 29, 2022

PsyBio Therapeutics Presents "How Genetically Modified Bacteria Can Yield Best-In-Class Psychedelics" At The Psychedelic Capital Conference
Jad Malaeb - Sponsored

Monday, January 24, 2022

Cannabis Movers & Shakers: Burns & Levinson, Water Ways, Chill Brands, Rubicon Organics
Jelena Martinovic

Monday, October 18, 2021

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman

Wednesday, October 13, 2021

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman

Monday, September 27, 2021

Psyched: Delic Buys 10 Ketamine Clinics For $10M, Atai Launches Ibogaine Human Trials, Small Pharma Concludes Phase 1 DMT Study
Natan Ponieman

Friday, July 02, 2021

Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Natan Ponieman

Wednesday, June 30, 2021

Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Natan Ponieman

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved